179 related articles for article (PubMed ID: 24742564)
1. [Pathologic diagnosis of colorectal cancer in the era of personalized therapy].
Lai M
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):73-6. PubMed ID: 24742564
[No Abstract] [Full Text] [Related]
2. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
Bertagnolli MM
J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
[No Abstract] [Full Text] [Related]
3. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
Hawkes E; Cunningham D
Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
[No Abstract] [Full Text] [Related]
4. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
5. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
Bass A
J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
[No Abstract] [Full Text] [Related]
6. Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.
Chu E
Oncology (Williston Park); 2014 Feb; 28(2):96. PubMed ID: 24701695
[No Abstract] [Full Text] [Related]
7. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
[No Abstract] [Full Text] [Related]
8. Mutation screening for KRAS and BRAF in metastatic colorectal cancer proves costly in relation to benefits.
Pharmacogenomics; 2013 Jan; 14(2):124. PubMed ID: 23447823
[No Abstract] [Full Text] [Related]
9. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
Wong R; Cunningham D
J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
[No Abstract] [Full Text] [Related]
10. Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer.
Lieberman R
Am J Ther; 2009; 16(6):477-9. PubMed ID: 19829092
[No Abstract] [Full Text] [Related]
11. Individualized therapy for metastatic colorectal cancer.
Silvestri A; Pin E; Huijbers A; Pellicani R; Parasido EM; Pierobon M; Petricoin E; Liotta L; Belluco C
J Intern Med; 2013 Jul; 274(1):1-24. PubMed ID: 23527888
[TBL] [Abstract][Full Text] [Related]
12. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
Hawkes E; Cunningham D
J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
[No Abstract] [Full Text] [Related]
13. Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors.
Seruca R; Velho S; Oliveira C; Leite M; Matos P; Jordan P
Expert Rev Gastroenterol Hepatol; 2009 Feb; 3(1):5-9. PubMed ID: 19210107
[No Abstract] [Full Text] [Related]
14. [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
Enlund F; Helenius G; Palmqvist R; Edsjö A; Sundström M
Lakartidningen; 2010 Feb 3-9; 107(5):255-9. PubMed ID: 20297566
[No Abstract] [Full Text] [Related]
15. [Biomarker for colorectal cancer].
Nagasaka T; Mori Y; Umeda Y; Fujiwara T
Nihon Rinsho; 2012 May; 70(5):802-8. PubMed ID: 22620004
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B.
Asaka S; Arai Y; Nishimura Y; Yamaguchi K; Ishikubo T; Yatsuoka T; Tanaka Y; Akagi K
Carcinogenesis; 2009 Mar; 30(3):494-9. PubMed ID: 19147861
[TBL] [Abstract][Full Text] [Related]
18. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
19. [Molecular pathology of lung cancer: key to personalized medicine].
Cheng L; Li Y; Zhang SB; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321
[No Abstract] [Full Text] [Related]
20. From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS.
Vauthey JN; Kopetz SE
Cancer; 2013 Dec; 119(23):4083-5. PubMed ID: 24105015
[No Abstract] [Full Text] [Related]
[Next] [New Search]